New strategies in insulin treatment: Analogues and noninvasive routes of administration

Fundamental and Clinical Pharmacology

Volumn 19, Issue 2, 2005, Pages 127-132

  Rungby, Jørgen ^a   Brock, Birgitte ^a   Schmitz, Ole ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Inhaled insulin; Insulin analogues; Insulin treatment

Indexed keywords

AERX; ASPART; DETEMIR; GLARGINE; GLULISINE; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; HYPOGLYCEMIA; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 17144362482     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2004.00306.x     Document Type: Review

References (47)

1. Rakatzi I., Ramrath S., Ledwig D. et al. A novel insulin analog with unique properties. Diabetes (2003) 52 2227-2238.
2. Howey D.C., Bowsher R.R., Brunelle R.L., Woodworth J.R. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes (1994) 43 396-402.
3. Vajo Z., Fawcett J., Duckworth W.C. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocrine Rev (2001) 22 706-717.
4. Brunelle B.L., Llewelyn J., Anderson J.H., Gale E.A., Koivisto V.A. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care (1998) 21 1726-1731.
5. Bolli G.B., Di Marchi R.D., Park G.D., Pramming S., Koivisto V.A. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia (1999) 42 1151-1167.
6. Persson B., Swahn M.L., Hjertberg R. et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res. Clin. Pract. (2002) 58 115-121.
7. Mecacci F., Carignani L., Cioni R. et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Eur. J. Obstet. Gynecol. Reprod. Biol. (2003) 111 19-24.
8. Jehle P.M., Aisenpreis U., Bundschu D., Keller F. Advantages of insulin lispro (short-acting) in terminal kidney failure. Fortschr. Med. (1999) 117 41-42.
9. Kotsanos J.G., Vignati L., Huster W. et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care (1997) 20 948-958.
10. Bode B., Weinstein R., Bell D. et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care (2002) 25 439-444.
11. Plank J., Wutte A., Brunner G. et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care (2002) 25 2053-2057.
12. Ashwell S.G., Home P.D. Insulin glargine: the first clinically useful extended-action insulin analogue. Expert Opin. Pharmacother. (2001) 2 1891-1902.
13. Hedman C.A., Lindström T., Arnqvist H.J. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care (2001) 24 1120-1121.
14. Bolli G.B., Di Marchi R.D., Park G.D. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia (1999) 42 1151-1167.
15. Danne T., Aman J., Schober E. et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care (2003) 26 2359-2364.
16. Dailey G., Rosenstock J., Moses R.G., Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care (2004) 27 2363-2368.
17. Rakattzi I., Seipke G., Eckel A. LysB3GluB29 insulin: a novel insulin analog with beta cell protective actions. Biochem. Biophys. Res. Commun. (2003) 310 852-859.
18. Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes (2000) 49 2142-2148.
19. Pritsche A., Schweitzer M.A., Häring H.-U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. (2003) 138 952-959.
20. Hamann A., Matthaei S., Rosak C., Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care (2003) 26 1738-1744.
21. Benedetti M.M., Humburg E., Dressler A., Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm. Metab. Res. (2003) 35 189-196.
22. Rossetti P., Pampanelli S., Fanelli C. et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care (2003) 26 1490-1496.
23. Murphy N.P., Keane S.M., Ong K.K. et al. Randomized crossover trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care (2003) 26 799-804.
24. Schober E., Schoenle E., Van Dyk J., Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care (2001) 24 2005-2006.
25. Rosenstock J., Schwartz S.L., Clark C.M. Jr., Park G.D., Donley D.W., Edwards M.B. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care (2001) 24 631-636.
26. Yki-Jarvinen H., Dressler A., Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care (2000) 23 1130-1136.
27. Witthaus E., Stewart J., Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet. Med. (2001) 18 619-625.
28. Myers S.R., Yakubu-Madus P.E., Johnson W.T. et al. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes (1997) 46 637-642.
29. Hermansen K., Madsbad S., Perrild H., Kristensen A., Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care (2001) 24 296-301.
30. Vague P., Selam J.L., Skeie S. et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care (2003) 26 590-596.
31. Hermansen K., Fontaine P., Kukolja K.K., Peterkova V., Leth G., Gall M.A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia (2004) [Epub ahead of print].
32. Kurtzhals P., Schaffer L., Sorensen A. et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 49 999-1005.
33. Colquitt J., Royle P., Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med. (2003) 20 863-866.
34. Gänsslen M. Über Inhalation von Insulin. Klin. Wochenschr. (1925) 4 71.
35. Laube B.L., Georgopoulus A., Adams G.K. III Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic subjects. JAMA (1993) 269 2106-2109.
36. Skyler J.S., Cefalu W.T., Kourides I.A. et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet (2001) 357 331-335.
37. Cefalu W.T., Skyler J.S., Kourides I.A. et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann. Intern. Med. (2001) 134 203-207.
38. Bindra S., Rosenstock J., Cefalu W.T. Inhaled insulin: a novel route for insulin delivery. Expert Opin. Investig. Drugs (2002) 11 687-691.
39. Hermansen K., Rönnemaa T., Petersen A.H., Bellaire S., Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care (2004) 27 162-167.
40. Himmelmann A., Jendle J., Mellén A., Petersen A.H., Dahl U.L., Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care (2003) 26 677-682.
41. Henry R.R., Mudaliar S.R., Howland W.C. III et al. Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care (2003) 26 764-769.
42. Gale E.A.M. Two cheers for inhaled insulin. Lancet (2001) 357 324-325.
43. Stoever J.A., Palmer J.P. Inhaled insulin and insulin antibodies; a new twist to an old debate. Diabetes Technol. Ther. (2002) 4 157-161.
44. Gerber R.A., Cappelleri J.C., Kourides I.A., Gelfand R.A. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes. Diabetes Care (2001) 24 1556-1559.
45. Royle P., Waugh N., McAuley L., McIntyre L., Thomas S. Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev (2003) 3 CD003890.
46. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. (1993) 329 977-986.
47. Madsbad S. Insulin analogues: have they changed insulin treatment and improved glycaemic control? Diabetes/Metab. Res. Rev. (2002) 18 21-28.